Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN. REBORN Study
University of Roma La Sapienza
60 participants
Sep 14, 2020
OBSERVATIONAL
Conditions
Summary
This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.
Eligibility
Inclusion Criteria2
- Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group);
- Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (control group).
Exclusion Criteria3
- Severe chronic kidney disease (stage 4-5);
- Clinical or laboratory signs of significant respiratory, cardiological and hepatobiliary disease;
- Other non-neuroendocrine malignancies.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04464122